Blodplasma används som läkemedel. : Men nationella, evidensbaserade behandlingsriktlinjer saknas
(2008) In Läkartidningen p.26-30- Abstract
- There are great regional variations in the use of plasma products. Evidence-based guidelines for plasma treatment are lacking. The Swedish market offers a non-commercial plasma product, produced by the hospital-based transfusion departments. There is also the commercial, virus-inactivated “SD plasma”. This is more expensive than the non-commercial plasma, yet it has not been shown to reduce the risk of complications. Thorough evaluation of the various plasma products and national guidelines for their use are warranted. In the absence of such guidelines, we recommend the non-commercial products for plasma treatment. SD plasma should primarily be considered to treat haemophilic patients, when specific factor based treatment is unavailable.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1299104
- author
- Palmblad, J ; Johnsson, H ; Lagerkranser, M ; Sundelin, G ; Wikman, A and Schött, Ulf LU
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Blood Component Transfusion: contraindications, Blood Component Transfusion: adverse effects, Blood Component Transfusion: utilization
- in
- Läkartidningen
- issue
- 1
- pages
- 26 - 30
- publisher
- Swedish Medical Association
- external identifiers
-
- pmid:18293742
- scopus:38549180559
- ISSN
- 0023-7205
- project
- Koagulation vid kirurgi och kritisk sjukdom
- language
- Swedish
- LU publication?
- no
- id
- 630ab702-db02-4a30-a534-3cfc5ae3b045 (old id 1299104)
- alternative location
- http://ltarkiv.lakartidningen.se/artNo34464
- date added to LUP
- 2016-04-01 14:50:34
- date last changed
- 2022-01-28 02:47:54
@article{630ab702-db02-4a30-a534-3cfc5ae3b045, abstract = {{There are great regional variations in the use of plasma products. Evidence-based guidelines for plasma treatment are lacking. The Swedish market offers a non-commercial plasma product, produced by the hospital-based transfusion departments. There is also the commercial, virus-inactivated “SD plasma”. This is more expensive than the non-commercial plasma, yet it has not been shown to reduce the risk of complications. Thorough evaluation of the various plasma products and national guidelines for their use are warranted. In the absence of such guidelines, we recommend the non-commercial products for plasma treatment. SD plasma should primarily be considered to treat haemophilic patients, when specific factor based treatment is unavailable.}}, author = {{Palmblad, J and Johnsson, H and Lagerkranser, M and Sundelin, G and Wikman, A and Schött, Ulf}}, issn = {{0023-7205}}, keywords = {{Blood Component Transfusion: contraindications; Blood Component Transfusion: adverse effects; Blood Component Transfusion: utilization}}, language = {{swe}}, number = {{1}}, pages = {{26--30}}, publisher = {{Swedish Medical Association}}, series = {{Läkartidningen}}, title = {{Blodplasma används som läkemedel. : Men nationella, evidensbaserade behandlingsriktlinjer saknas}}, url = {{http://ltarkiv.lakartidningen.se/artNo34464}}, year = {{2008}}, }